التفاصيل البيبلوغرافية
| العنوان: |
Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. |
| المؤلفون: |
Yale, Jean-François, Roborel de Climens, Aude, Aggarwal, Naresh, Dex, Terry, Gerstein, Hertzel C., Harris, Stewart, Hramiak, Irene, Stewart, John, Leiter, Lawrence A. |
| المصدر: |
Diabetes Therapy; Feb2023, Vol. 14 Issue 2, p377-386, 10p |
| مصطلحات موضوعية: |
MEDICAL personnel, TYPE 2 diabetes, GLUCAGON-like peptide-1 receptor, INSULIN receptors, GLUCAGON-like peptide-1 agonists |
| مستخلص: |
Introduction: For people with type 2 diabetes mellitus who do not achieve glycated hemoglobin A1C targets after treatment with basal insulin therapies, additional therapy with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) may be required. One option is to use a once-daily fixed-ratio combination (FRC) of basal insulin and a GLP-1 RA such as iGlarLixi (which is composed of insulin glargine 100 U/ml and lixisenatide). However, the ease of transitioning from basal insulin to an FRC has not been studied. Methods: This sub-study of the LixiLan ONE CAN trial (NCT03767543) was conducted to assess the ease of transitioning from insulin glargine 100 U/ml to the FRC, iGlarLixi, using the iGlarLixi SoloStar® pen. Patients completed a validated, ten-item questionnaire, and healthcare professionals (HCPs) completed a five-item questionnaire. Both questionnaires used either five-point Likert scales or yes/no answers as appropriate, and both were completed after 4 weeks of using the iGlarLixi SoloStar pen. Results: Overall, 95.1% of patients reported that the iGlarLixi Solostar pen was "easy" or "very easy" to use. Similarly, 100% of HCPs reported that it was "easy" or "very easy" to train people to use the pen. Nearly all participants (97.5% of patients and 94% of HCPs) responded that they would recommend the iGlarLixi Solostar pen to others. Conclusions: These results suggest that during the transition from insulin glargine 100 U/ml to iGlarLixi, there were no difficulties associated with using the iGlarLixi SoloStar pen injector regarding instruction for use by HCPs or actual use by the majority of patients. The results indicate a broad consensus between patients and HCPs on the relative simplicity of transitioning from self-administration of insulin glargine 100 U/ml to iGlarLixi. Trial Registration: ClinicalTrials.gov identifier, NCT03767543; Date of registration: December 6, 2018; Retrospectively registered. Plain Language Summary: Many people take basal insulin to control their blood sugar, but for those in whom basal insulin injections do not work well enough to achieve their target blood glucose, treatment needs to be advanced. One option to do this is with a fixed-ratio combination therapy that combines basal insulin with a GLP-1 receptor agonist, such as iGlarLixi. Both basal insulin and fixed-ratio combination therapies are administered using injection pens, but the ease of transitioning from a basal insulin pen to a fixed-ratio combination pen has not been assessed. In this study, people with type 2 diabetes who had previously received the basal insulin insulin glargine 100 U/ml using a SoloStar® pen, and who transitioned to the iGlarLixi SoloStar pen, were asked to complete a questionnaire to rate their experience of using the new pen injector after 4 weeks of use. Their doctors also completed a questionnaire at the same time. Over 95% of patients reported that the iGlarLixi SoloStar® pen was "easy" or "very easy" to use, and all of the doctors reported that it was "easy" or "very easy" to train people to use it. Nearly all of those who completed questionnaires (97.5% of patients and 94% of doctors) said that they would recommend use of the iGlarLixi Solostar pen to others. These results suggest that both patients and their doctors thought that it was relatively easy to transition from self-administration of insulin glargine 100 U/ml to iGlarLixi using the SoloStar pen injector. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diabetes Therapy is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder